Saturday 17 October 2026
Export CV’s income statement to Excel — free account
CapsoVision, Inc.
CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 92.6% and free cash flow fell 84.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.53
0.08
+1.24%
Follow CV
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 3.43 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 15.37 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 90 | 28 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.13 | 0.48 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 12 | 14 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 54.24 | 52.92 | |||||
| EBT | — | — | — | — | — | — | — | — | (20) | (25) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | (169.16) | (186.59) | |||||
| Net income | — | — | — | — | — | — | — | — | (20) | (25) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 5.82 | 0.55 | ||||
| Earnings | — | — | — | — | — | — | — | — | (9.85) | (1.03) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (9.95) | (0.93) | |||||
| Capex | — | — | — | — | — | — | — | — | (0.08) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (10.02) | (0.93) | |||||
| Book value | — | — | — | — | — | — | — | — | (64.11) | 0.54 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 25 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.67 | 19.37 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 19.80 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.58 | 18.62 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.32) | (11.00) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (20) | (23) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (20) | (23) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 13 | 12 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | (9) | (10) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (130) | 13 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (144.79) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (506.59) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 43.55 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
CapsoVision, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SENS Senseonics Holdings, Inc. | $435.2M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| OFIX ORTHOFIX MEDICAL INC. | $390.6M | — (loss-making) | — (loss-making) | +3.85% (above 0%: growing) | n/m | −516.58% (below 0%: shrinking) | 70.97% | (3.86%) | Compare |
| SI Shoulder Innovations, Inc. | $382.4M | — (loss-making) | — (loss-making) | +55.95% (above 0%: growing) | n/m | −52.42% (below 0%: shrinking) | 78.26% | (58.43%) | Compare |
| VMD Viemed Healthcare, Inc. | $371.4M | 24.9× | 21.9× | +23.85% (above 0%: growing) | −12.50% (below 0%: shrinking) | −18.15% (below 0%: shrinking) | 57.68% | 6.39% | Compare |
| CV CapsoVision, Inc. | $343.2M | 2.1× | — (loss-making) | +9.89% (above 0%: growing) | n/m | −84.44% (below 0%: shrinking) | 51.36% | (208.07%) | |
| RCEL Avita Medical Inc. | $333.1M | — (loss-making) | — (loss-making) | +17.83% (above 0%: growing) | n/m | +66.52% (above 0%: growing) | 81.87% | (28.42%) | Compare |
| CLPT ClearPoint Neuro, Inc. | $294.1M | — (loss-making) | — (loss-making) | +18.07% (above 0%: growing) | n/m | −173.51% (below 0%: shrinking) | 61.67% | (94.15%) | Compare |
| QSI Quantum-Si Incorporated | $286.7M | — (loss-making) | — (loss-making) | −41.79% (below 0%: shrinking) | n/m | +9.75% (above 0%: growing) | 50.00% | (7,450.29%) | Compare |
| INFU InfuSystems Holdings, Inc. | $277.2M | 31.7× | 21.7× | +2.59% (above 0%: growing) | +33.33% (above 0%: growing) | −66.54% (below 0%: shrinking) | 57.98% | 11.24% | Compare |
| Median of peers | $352.2M | — | — | +17.95% | — | −59.48% | 60.39% | (43.42%) |
CapsoVision, Inc. (CV) key facts
- Strength: CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024.
- CapsoVision, Inc. (CV) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CV traded at $6.53, a market capitalization of $343.2 million.
- Return on equity was 43.6% and debt-to-equity 0.00.
- Its Altman Z-score is 17.04 (safe zone) for fiscal 2025.